Edris Badreddin

Director Edris Badreddin sold 115,471 shares at $29.44 for $3,399,466.24 in 5 separate transactions on 2026-01-21, reducing holdings 85.4%

Edris Badreddin executed 5 separate sales totaling 115,471 shares for $3,399,466.24 at $29.44 per share, reducing his post-transaction holdings to 19,820 shares from a pre-transaction position of 135,291 shares. The director's sales occurred near the 52-week high of $30.03 (transaction price $29.44 is 4.7% below peak), and the stock has gained 88.5% over 90 days and 4.8% over 30 days. Edgewise Therapeutics reported a net loss of $40,666,000.00 for the most recent full fiscal year, indicating the company remains unprofitable. Across his cross-ticker track record, Badreddin's 14 prior open-market sells showed an average 90-day well-timed rate of 50.00%, suggesting historical timing patterns that merit observation alongside this substantial director-level position reduction near recent price peaks in an unprofitable company.

COO Edris Badreddin sells 20,000 SWTX shares across 4 transactions for $1,084,592.24; stock up 41.2% in 30 days but down 15.6% from 52-week high.

Edris Badreddin, Chief Operating Officer, executed 4 separate sales totaling 20,000 shares (20.0K shares) for $1,084,592.24 at a blended average price of $54.23 on 2025-03-03, reducing his holdings by 10.5% to 169.7K shares. The timing is contextually mixed: the stock has rallied 41.2% over the prior 30 days and 21.2% over the prior 90 days, yet remains 15.6% below its 52-week high of $59.93. Within the same ticker (SWTX), his prior 4 measurable sells (excluding a recent 2025-02-10 sale) showed 0 well-timed outcomes at the 90-day mark—all four resulted in positive 90-day returns after the sale, meaning the stock rose post-sale. Company fundamentals show rapid revenue growth of 3417.3% year-over-year, but the business remains unprofitable with a net loss of $-53,530,000.00 against quarterly revenue of $49,301,000.00. The magnitude and frequency of this insider's sales merit observation, though the pattern does not yet suggest prescience about future stock direction.

SpringWorks COO sold 30.0K shares at $53.13; stock now at $59.28 (+0.0% from 52-week high); company unprofitable.

Edris Badreddin, SpringWorks Chief Operating Officer, sold 30,000 shares on 2025-02-10 at $53.13 per share, reducing holdings by 13.7% from 219.7K to 189.7K shares. The sale occurred at $5.98 below the current price of $59.28, which stands at the 52-week high. At SpringWorks, his prior sell track record shows a mixed record: three sales on 2024-09-03 realized 90-day declines of -20.6%, -22.6%, and -24.4%, while two December 2024 sales have measurable 30-day returns of -13.6% and -14.6%. The company remains unprofitable with $-53.5M net income on $49.3M quarterly revenue, despite a $4.4B market cap. The divergence between the transaction price and current market price, combined with his uneven timing history at this ticker, warrants investor attention to whether this sale foreshadows near-term weakness or represents a discrete liquidity event.

COO Edris Badreddin sold 20,000 shares at $41.97 avg; holds 209.6K shares post-sale at unprofitable biotech.

Edris Badreddin, COO of SpringWorks Therapeutics, executed 2 separate sales totaling 20,000 shares on 2024-12-03 for $839,335.79 at a blended average price of $41.97, reducing his holdings by 8.7% to 209.6K shares. The current price of $41.75 is 20.5% below the 52-week high of $52.50, and the stock has risen +32.2% in the past 30 days following a recent sell pattern: his prior 5 trades at SWTX (all sells in June and September 2024) showed mixed 90-day outcomes, with only 40% well-timed on the 90-day horizon. His cross-ticker track record of 7 prior sells shows an average 90-day return of +2.0%, indicating the stock typically rose after his sales—a pattern of poorly-timed exits. The sale occurs at a company with quarterly revenue of $49.3M but a negative net income of $-53.5M, reflecting unprofitability in the most recent full fiscal year.

COO Edris Badreddin sells 20,000 shares of SWTX for $812,954.35 at blended average price $40.65

Edris Badreddin, Chief Operating Officer, executed 3 separate sales totaling 20,000 shares for $812,954.35 on 2024-09-03, reducing holdings from 249,600 to 229,600 shares (-8.0%). The transaction occurred at blended average price $40.65, near the current price of $40.98. SpringWorks is unprofitable with most recent quarterly revenue of $59,733,000.00 against net loss of $-39,919,000.00. In Badreddin's cross-ticker track record of prior sells, average 90-day return was +2.1% (a 25.00% well-timed rate, meaning most prior sells were followed by stock declines). At SWTX specifically, his 4 prior sales from 2024-06-03 were predominantly poorly timed, with only 1 of 4 well-timed at the 90-day mark; three showed negative 30-day returns but mixed 90-day outcomes, suggesting the stock recovered post-sale.